EUVIMEDEUVIMED entdecken
Crossref

Rethinking Pathogenesis of Primary Sclerosing Cholangitis

Münevver Demir, Jakob Weglage, Michael Sigal iD

Seminars in Liver Disease · 04.11.2026

DOI: 10.1055/a-2983-6480 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Seminars in Liver Disease, online erschienen am 04.11.2026. Verfasst von Münevver Demir und 2 weiteren Autor:innen. Beteiligte Einrichtung: "Charité - Universitätsmedizin" Berlin, Department of Hepatology and Gastroenterology, Germany, Berlin. Die Arbeit nennt 157 Literaturangaben. Gefördert von: DFG, ERC, BMBF Consortium PACETHERAPY.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by progressive fibroinflammatory injury of intrahepatic and extrahepatic bile ducts that may lead to cirrhosis, hepatobiliary malignancy, and death, with liver transplantation representing the only effective intervention in end-stage disease. Rather than a single dominant pathomechanism, the data support a model in which four axes—bile acid metabolism, the intestinal microbiome and gut barrier, biliary epithelial dysfunction, and Th17-skewed immune dysregulation—are reciprocally coupled and converge on a shared periductal fibrogenic output dominated by TGF-β signaling. This review summarizes key mechanistic advances from genetic, epigenomic, single-cell, spatial transcriptomic, and microbiome studies. These investigations implicate antigen presentation pathways, Th17-skewed immune responses, cholangiocyte senescence and profibrotic signaling, and disrupted gut–liver communication as central drivers of chronic biliary injury. Emerging spatial and multi-omics approaches further reveal complex cellular crosstalk among cholangiocytes, immune cells, macrophages, and mesenchymal populations within portal inflammatory niches. We discuss evolving biomarkers and recent clinical trial data targeting bile acid metabolism, fibrosis, the microbiome, and immune pathways. In conclusion, research data suggest viewing PSC as a network disease, which provides a unifying framework for disease pathogenesis and may enable biomarker-guided patient stratification and mechanism-based therapy development targeting distinct pathogenic pathways.

Autor:innen und Institutionen

  • "Charité - Universitätsmedizin" Berlin, Department of Hepatology and Gastroenterology, Germany, Berlin.
  • Charité - Universitätsmedizin Berlin, Cluster of Excellence ImmunoPreCept, Germany, Berlin.

ORCID-Profile: Michael Sigal

Förderung

  • DFG
  • ERC
  • BMBF Consortium PACETHERAPY

Zitieren

APA

Demir, M., Weglage, J., & Sigal, M. (2026). Rethinking Pathogenesis of Primary Sclerosing Cholangitis. Seminars in Liver Disease. https://doi.org/10.1055/a-2983-6480

Vancouver

Demir M, Weglage J, Sigal M. Rethinking Pathogenesis of Primary Sclerosing Cholangitis. Seminars in Liver Disease. 2026. doi:10.1055/a-2983-6480

BibTeX
@article{Demir2026,
  author = {Demir, Münevver and Weglage, Jakob and Sigal, Michael},
  title = {Rethinking Pathogenesis of Primary Sclerosing Cholangitis},
  journal = {Seminars in Liver Disease},
  year = {2026},
  doi = {10.1055/a-2983-6480}
}
Kostenlos starten →